Proprotein subtilisin/kexin type 9 (PCSK9) inhibitors such as alirocumab may provide clinical benefits in patients with low-density lipoprotein cholesterol (LDL-C) levels near 70 mg/dL and recent acute coronary syndromes (ACS) only when lipoprotein(a), or Lp(a), is elevated, a post hoc analysis of trial data suggests.